🇺🇸 FDA
Patent

US 8383805

RNAi modulation of SCAP and therapeutic uses thereof

granted A61PA61P1/00A61P1/16

Quick answer

US patent 8383805 (RNAi modulation of SCAP and therapeutic uses thereof) held by The Board of Regents of the University of Texas System expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P1/00, A61P1/16, A61P3/00, A61P3/04